IMG-7289-CTP-202 Phase 2 Myeloproliferative Neoplasms Study
Research type
Research Study
Full title
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
IRAS ID
303091
Contact name
Claire Harrison
Contact email
Sponsor organisation
Imago BioSciences Inc.
Eudract number
2021-002452-37
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This is a clinical study of IMG-7289 (bomedemstat), a new drug that blocks the activity of an enzyme called LSD1. The study is being conducted in patients with Myeloproliferative Neoplasms such as Myelofibrosis (MF) and Essential Thrombocythemia (ET). LSD1 is essential for some blood cells to develop. Blocking LSD1 is expected to be a useful treatment for patients with MPNs. This study will enrol approx 80 participants over the age of 18 who have been receiving bomedemstat under a feeder protocol such as IMG-7289-CTP-102 or IMG-7289-CTP-201. This all-comers extension study will enable patients to receive bomedemstat until such time as bomedemstat is available commercially as long as they continue to benefit from treatment. The dose of bomedemstat will be adjusted depending on how the participant’s platelet count continues to respond to treatment. Patients should roll into this extension study without dose interruption (however, 14 days interruption is permitted) and will be treated in 24 week Treatment Periods. The aim of this study is to continue to assess safety, tolerability and efficacy of bomedemstat in patients that have already received the IMP in a prior study.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
21/EM/0244
Date of REC Opinion
17 Dec 2021
REC opinion
Further Information Favourable Opinion